Active Ingredient History
Bendamustine, brand name Treanda, is a chemotherapeutic agent that displays a unique pattern of cytotoxicity compared with conventional alkylating agents. Treanda is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL), in addition Trenda in phase III of clinical trial for the treatment patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative. Mechlorethamine and its derivatives dissociate into electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties. The bifunctional covalent linkage can lead to cell death via several pathways. The exact mechanism of action of bendamustine remains unknown. Molecular analyses have revealed that bendamustine differs from other alkylating agents in its mechanism of action. Differences have been observed about its effects on DNA repair and cell cycle progression. Moreover, bendamustine can induce cell death through both apoptotic and nonapoptotic pathways, thereby retaining activity even in cells without a functional apoptotic pathway. Bendamustine possesses the typical adverse reactions for the nitrogen mustards, and include nausea, fatigue, vomiting, diarrhea, fever, constipation, loss of appetite, cough, headache, unintentional weight loss. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acquired Immunodeficiency Syndrome (Phase 2/Phase 3)
Amyloidosis (Phase 2)
Anemia (Phase 2)
Anemia, Hemolytic, Autoimmune (Phase 2)
Astrocytoma (Phase 2)
Behavior Therapy (Phase 2)
Bendamustine Hydrochloride (Phase 3)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Burkitt Lymphoma (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Colorectal Neoplasms (Phase 1)
Cyclin D1 (Phase 2)
Fever (Phase 2)
Glioblastoma (Phase 2)
Gliosarcoma (Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 2)
HIV Infections (Phase 2/Phase 3)
Hodgkin Disease (Phase 3)
Hyperplasia (Phase 2)
Immune System Diseases (Phase 1)
Immunoglobulin Light-chain Amyloidosis (Phase 2)
Immunoproliferative Disorders (Phase 1)
Infections (Phase 2)
Infectious Mononucleosis (Phase 2)
Intestinal Neoplasms (Phase 1/Phase 2)
Intraocular Lymphoma (Phase 2)
Leukemia (Phase 3)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Hairy Cell (Phase 2)
Leukemia, Large Granular Lymphocytic (Phase 1)
Leukemia, Lymphoid (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Plasma Cell (Phase 1)
Leukemia, Prolymphocytic (Phase 2)
Leukemia, Prolymphocytic, B-Cell (Phase 1)
Lung Neoplasms (Phase 2)
Lymphadenopathy (Phase 2)
Lymphatic Diseases (Phase 2)
Lymphocytosis (Phase 2)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 3)
Lymphoma, Follicular (Phase 4)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2/Phase 3)
Lymphoma, Mantle-Cell (Phase 3)
Lymphoma, T-Cell (Phase 3)
Lymphoma, T-Cell, Cutaneous (Phase 1)
Lymphoma, T-Cell, Peripheral (Phase 2)
Lymphomatoid Granulomatosis (Phase 2)
Lymphomatoid Papulosis (Phase 1)
Lymphoproliferative Disorders (Phase 2)
Multiple Myeloma (Phase 3)
Mycosis Fungoides (Phase 1)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neoplasms (Phase 3)
Neuroblastoma (Phase 1)
Oligodendroglioma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 1)
Plasmacytoma (Phase 2)
Polymorphism, Genetic (Phase 2)
Prostatic Neoplasms (Phase 1)
Renal Insufficiency, Chronic (Phase 2)
Safety (Phase 1/Phase 2)
Sarcoma (Phase 2)
Sezary Syndrome (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Sweat (Phase 2)
Testicular Neoplasms (Phase 1/Phase 2)
Thrombocytopenia (Phase 2)
Translocation, Genetic (Phase 2)
Transplantation (Phase 1)
Treatment Outcome (Phase 1/Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
Weight Loss (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
